I thank all the members from across the chamber who signed my motion, helping to raise awareness of idiopathic pulmonary fibrosis. It is a little-known condition, but it is one that around 2,500 of our constituents across Scotland are living with today.
I used to joke that I had the only grass in my street that never got any longer; I would go out to work and when I came home at night, it had been mysteriously cut, because that is what dads did. I remember, though, that in the summer of 2011, I noticed that the grass was getting a little bit longer between those cuts. Dad was not without his health challenges—he had suffered a couple of heart attacks over the years and had been diagnosed with heart disease and diabetes—but he was a strong and active man.
When I asked him whether he was feeling okay and whether he wanted me to cut my grass, he said, “Don’t be daft. I’m fine—just a little tired. Anyway, I’ve seen the state of your lawn after you’ve cut it.” A few weeks later, Dad developed a dry cough. Again, he brushed aside my concerns. Soon the cough became a chest infection and I convinced him to go to the general practitioner, who treated him with antibiotics. However, the infections became more frequent, taking longer to treat and longer to recover from each time.
The GP also detected a build-up of fluid on Dad’s lungs. That was put down to his heart disease and doctors began adjusting his medication but to little effect. Tiredness became breathlessness when he walked even the shortest distance. Dad’s GP prescribed oxygen at home to help to ease the symptoms—a few hours a day to begin with but soon all day when he was at home.
More than a year after the first symptoms, the hospital admissions became more frequent, but there was no real diagnosis other than Dad’s long-standing heart disease. In early 2013, Dad was admitted to hospital yet again, when his breathing became more and more difficult. Then one day in hospital, out of the blue, he said to me, “Good news! They’ve got to the bottom of what’s wrong at last—I’ve got idiopathic pulmonary fibrosis.”
I had never heard of it, but I remember leaving hospital that day feeling quite upbeat. After months of frustration watching the one person who never let anything get in his way battling just to walk even the shortest distance without being out of breath, I thought, “At last—they’ve got to the bottom of the problem. They can now get on with fixing it.”
I went home and did what we all do. I did a Google search of the condition to find out what IPF was and what could be done. The results told me that IPF was scarring of the lungs. It caused the lungs to harden, making it more difficult to breathe. Then I read on and I remember feeling sick to the pit of my stomach when I did. It said that the scar tissue cannot be repaired. There is no cure for IPF. Survivability is worse than for most cancers. Few survive more than three to five years after diagnosis. There are no drugs that would make any meaningful difference. In fact, I remember Dad’s consultant prescribing steroids but openly admitting that they were unlikely to have any effect at all.
Dad continued to battle his condition, but he began to deteriorate further. The impact of IPF was simply putting too much pressure on his heart condition. Almost two years after first showing symptoms of IPF, but just weeks after being diagnosed, he passed away on 8 May 2013.
What causes IPF remains largely unknown. Researchers believe that some people may be genetically predisposed to develop the condition. They also believe that the body creates fibrosis, the scarring that I referred to earlier, in response to injury to the lung—for example, in those who have been exposed at work to dust. Certainly, Dad’s background was that he had worked in an industrial setting for many decades.
That highlights the issue of inequalities in lung disease. Incidence tends to be higher in post-industrial areas, meaning not only that rates in Scotland are higher than the United Kingdom average but that the rate of lung disease-related deaths in Glasgow, with its industrial background, is almost double that of its neighbouring local authorities of East Dunbartonshire and East Renfrewshire.
A serious shortage of data on IPF makes it difficult to get a precise idea of the impact of those regional inequalities, with neither the national health service Information Services Division nor the Scottish Government holding data centrally on how many people are diagnosed with IPF. However, from the information that we have, we know that the problem of IPF is growing, with its prevalence and mortality increasing here and across Europe.
The condition remains poorly understood; its non-specific symptoms make it challenging to recognise and the high risk of fatality that is posed by a biopsy makes it difficult to diagnose. More than a third of people with IPF have been misdiagnosed, with the condition commonly mistaken for asthma, chronic obstructive pulmonary disease or heart problems. More than half of patients waited more than six months before they were diagnosed, with one in five waiting more than two years.
The Government’s forthcoming respiratory care action plan will be a chance to change the situation and make much-needed progress in both the diagnosis and the treatment of IPF. It is critical that GPs and other healthcare practitioners have the knowledge and training to recognise symptoms and to know to run the appropriate tests. A lung cancer screening programme, at least in the form of a pilot, would help to detect lung cancer earlier, rather than the current position in which half of all lung cancer diagnoses in Scotland are at the most advanced stage. It would also detect other lung conditions such as IPF. There needs to be greater understanding of how IPF relates to other conditions and how it presents, for example, in people with heart disease.
More also needs to be done to improve treatment. I said earlier that, when Dad was diagnosed, no drugs could make a difference, but today, new medications, such as nintedanib and pirfenidone, have been shown to slow down the progression of the condition, not only extending lives but improving quality of life. However, those medications are available only to people with lung function of below 80 per cent, excluding many who would benefit from early intervention to improve their life expectancy. There is also a postcode lottery in the prescribing of such medication.
Although those medications can help to slow down the scarring process, IPF cannot be stopped entirely. That is why long-term specialist support is essential. Specialist nurses have a vital role to play in delivering the high-quality expert care that those who live with IPF need. At present, provision is woefully lacking. Only four health boards across Scotland have access to any specialist nurses who are trained in dealing with IPF. Their time is incredibly stretched; for example, just one specialist nurse covers the entirety of NHS Greater Glasgow and Clyde. The respiratory care action plan should therefore include an increase in specialist nurses for IPF across Scotland as a key priority.
As well as access to specialist nurses being very limited, access to pulmonary rehabilitation varies significantly. Pulmonary rehabilitation is typically associated with the treatment of COPD, but it can be useful to those with IPF. It equips people with exercises to improve their fitness, helps them to control the physical symptoms of their condition and acts as a source of support and information from health professionals and from peers with similar conditions. Despite those clear benefits, the referral rate in some areas is as low as 2 per cent, with capacity consistently falling short of demand. The charity Chest Heart & Stroke Scotland is campaigning vigorously for improvements in that regard.
Much more can and needs to be done to improve the diagnosis and treatment of idiopathic pulmonary fibrosis and I hope that the Government’s respiratory care action plan will help to deliver it. The outstanding work of the British Lung Foundation to campaign so effectively in all areas of lung health will also play a vital part, and I hope to play my part as the IPF champion.
In the long term, we should not settle for managing the symptoms of a fatal condition. In the past six years since my dad passed away, we have seen advances in the medicines that are available. With enough investment in research, we can turn the focus from managing this dreadful condition to better understanding its causes and, ultimately, curing or preventing idiopathic pulmonary fibrosis.